Evidence on the validity of drug targets from randomized trials is reliable but typically
expensive and slow to obtain. In contrast, evidence from conventional observational …

While comorbidity between coronary heart disease (CHD) and depression is evident, it is
unclear whether the two diseases have shared underlying mechanisms. We performed a range …

Drugs whose targets have genetic evidence to support efficacy and safety are more likely to
be approved after clinical development. In this paper, we provide an overview of how natural …

Background Selection bias affects Mendelian randomization investigations when selection
into the study sample depends on a collider between the genetic variant and confounders of …

CORRESPONDENCE lifetime smoking score were also associated with increased risk of
severe COVID-19 with respiratory failure and hospitalization with COVID-19 (Figure). Similar …

Background: Evidence from randomized trials has shown that therapies that lower LDL (low-density
lipoprotein)-cholesterol and triglycerides reduce coronary artery disease (CAD) risk. …

Genetic studies of disease progression can be used to identify factors that may influence
survival or prognosis, which may differ from factors that influence on disease susceptibility. …

Background A robust method for Mendelian randomization does not require all genetic variants
to be valid instruments to give consistent estimates of a causal parameter. Several such …

Background Dyslipidaemia is highly prevalent in individuals with type 2 diabetes mellitus (T2DM).
Numerous studies have sought to disentangle the causal relationship between …

Mendelian randomization (MR) is the use of genetic variants to assess the existence of a
causal relationship between a risk factor and an outcome of interest. Here, we focus on two‐…